Morgan Stanley’s Biostar Pharmaceuticals, Inc. BSPM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-3,950
| Closed | -$9K | – | 7003 |
|
|
2018
Q2 | $9K | Buy |
3,950
+3,926
| +16,358% | +$9.82K | ﹤0.01% | 6344 |
|
|
2018
Q1 | $0 | Hold |
24
| – | – | ﹤0.01% | 6895 |
|
|
2017
Q4 | $0 | Hold |
24
| – | – | ﹤0.01% | 6876 |
|
|
2017
Q3 | $0 | Hold |
24
| – | – | ﹤0.01% | 6799 |
|
|
2017
Q2 | $0 | Sell |
24
-31,150
| -100% | -$54.2K | ﹤0.01% | 6817 |
|
|
2017
Q1 | $72K | Sell |
31,174
-224
| -0.7% | -$588 | ﹤0.01% | 5720 |
|
|
2016
Q4 | $92K | Buy |
31,398
+26,747
| +575% | +$91.5K | ﹤0.01% | 5600 |
|
|
2016
Q3 | $17K | Buy |
4,651
+4,627
| +19,279% | +$16.9K | ﹤0.01% | 5968 |
|
|
2016
Q2 | $0 | Sell |
24
-4
| -14% | -$9 | ﹤0.01% | 6958 |
|
|
2016
Q1 | $0 | Hold |
28
| – | – | ﹤0.01% | 6955 |
|
|
2015
Q4 | $0 | Buy |
28
+4
| +17% | +$17 | ﹤0.01% | 6984 |
|
|
2015
Q3 | $0 | Sell |
24
-4
| -14% | -$22 | ﹤0.01% | 6902 |
|
|
2015
Q2 | $0 | Hold |
28
| – | – | ﹤0.01% | 6901 |
|
|
2015
Q1 | $0 | Sell |
28
-1,428
| -98% | -$11.5K | ﹤0.01% | 6800 |
|
|
2014
Q4 | $12K | Buy |
1,456
+1,428
| +5,100% | +$13.6K | ﹤0.01% | 6185 |
|
|
2014
Q3 | $0 | Buy |
28
+1
| +4% | +$11 | ﹤0.01% | 6781 |
|
|
2014
Q2 | $0 | Sell |
27
-479
| -95% | -$5.29K | ﹤0.01% | 6708 |
|
|
2014
Q1 | $7K | Buy |
506
+482
| +2,008% | +$7.64K | ﹤0.01% | 6201 |
|
|
2013
Q4 | $0 | Buy |
+24
| New | +$259 | ﹤0.01% | 6390 |
|
Morgan Stanley's BSPM Position: Q3 2018 in Review
Morgan Stanley sold out of Biostar Pharmaceuticals, Inc. (BSPM) in Q3 2018, closing a stake of 3,950 shares — an estimated $9K sold.
Morgan Stanley first reported a position in BSPM in Q4 2013 and held it in 19 quarters. The position peaked at $92K in Q4 2016. 0 funds tracked by Wall St. Rank hold BSPM as of Q3 2018.
- Morgan Stanley reported no remaining Biostar Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
- Morgan Stanley sold 3,950 Biostar Pharmaceuticals, Inc. shares in Q3 2018, an estimated $9K.
- Morgan Stanley first reported a position in Biostar Pharmaceuticals, Inc. in Q4 2013 and held it in 19 quarters.
- Morgan Stanley's Biostar Pharmaceuticals, Inc. position peaked at $92K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Biostar Pharmaceuticals, Inc. as of Q3 2018.
Based on Morgan Stanley's 13F filing for Q3 2018, filed 14 Nov 2018.